The Food and Drug Administration (FDA) has increased its efforts to follow through on its commitment to provide guidance to stakeholders on the regulatory landscape for products containing CBD. On May 31, 2019, the FDA held a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale
Khelin Aiken supports life sciences companies as they develop innovative products and bring them to market, with particular focus on therapeutic product development plans and marketing applications for prescription drugs, including therapeutic biologics and generics. She also advises on policies related to over-the-counter (OTC) drugs. Prior to joining McDermott, Khelin served as regulatory counsel at the Food and Drug Administration (FDA) in the Center for Drug Evaluation and Research, first in the Office of Regulatory Policy, and most recently in the Office of New Drugs with the Therapeutic Biologics and Biosimilars Staff. Read Khelin N. Aiken's full bio.